Dry EyeNCT07329712
Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy
An observational study of Dry Eye and Meibomian Gland Dysfunction (Disorder), run by Singapore National Eye Centre at 1 site in Singapore.
Trial summary
The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Dry Eye, Meibomian Gland Dysfunction (Disorder)
- How many people
- 30 participants
- Where
- 1 siteSingapore
- Study dates
- 5 Nov 2025to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient undergoing low level light therapy that met the study inclusion and exclusion
Who may be able to join
- Must be eligible for, and have consented for low level light therapy
- Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye
- Ability to give informed consent.
- Age more or equals to 21 years old.
Who cannot join
- Patients who are unable to or decline to give consent.
- Age less than 21 years old.
- Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.
- Patients not suitable for low level lighttherapy:
- Pregnant
- Fitted with pacemakers, metal, electrical, acoustic prosthetics
Show all 12Show fewer
- Epilepsy, cardiac rhythm or frequency disorders
- Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months
- Uncontrolled hypertension or severe diabetes
- Open wounds on eyelid or skin
- Evolving cancer or hepatitis
- Blood anticoagulant or coagulation defect
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Jiayi Lee, MSc contact
Singapore1 site, 1 recruiting
- Recruiting
Singapore Eye Research Insititute
Singapore
Jiayi Lee, MSc, 65767200, lee.jiayi1@singhealth.com.sg
About this study
The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.
- Conditions
- Dry Eye, Meibomian Gland Dysfunction (Disorder)
- Keywords
- Dry Eye, low level light therapy, Eyelight, Tears proteomics, tear cytokine, MGD
- Medical subject headings
- Dry Eye Syndromes, Meibomian Gland Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients undergoing low level light therapy | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy
Aim 1: Tear proteomic profile of MGD patients with DED pre- and post-treatment with LLLT will be profiled Aim 2: Baseline tear cytokine levels will be measured using the novel Olink 500-plex technology in DED patients with MGD undergoing LLLT
Measured: Baseline visit and Post Baseline visit 3 months (+3 weeks).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2026
- Study start5 Nov 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry EyeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Singapore National Eye Centre
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Louis Tong, Singapore National Eye Centre
- Investigators
- Louis Tong, PhD, Principal investigator, Singapore Eye Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07329712
- Sponsor's protocol ID
- 2025-0870
- Other IDs
- 2025-0870
- Status last verified
- Nov 2025
- First submitted
- 21 Dec 2025
- Last updated
- 9 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy
- ClinicalTrials.gov ID
- NCT07329712
- Acronym / sponsor ID
- 2025-0870
- Conditions
- Dry Eye, Meibomian Gland Dysfunction (Disorder)
- Keywords
- Dry Eye, low level light therapy, Eyelight, Tears proteomics, tear cytokine, MGD
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Singapore National Eye CentreOther government
- Study start
- 5 Nov 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 9 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients undergoing low level light therapy | – | – |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient undergoing low level light therapy that met the study inclusion and exclusion
Key inclusion criteria (4 listed)
- Must be eligible for, and have consented for low level light therapy
- Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye
- Ability to give informed consent.
- Age more or equals to 21 years old.
Key exclusion criteria (12 listed)
- Patients who are unable to or decline to give consent.
- Age less than 21 years old.
- Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.
- Patients not suitable for low level lighttherapy:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy
Time frame: Baseline visit and Post Baseline visit 3 months (+3 weeks).
Aim 1: Tear proteomic profile of MGD patients with DED pre- and post-treatment with LLLT will be profiled Aim 2: Baseline tear cytokine levels will be measured using the novel Olink 500-plex technology in DED patients with MGD undergoing LLLT
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2026.
Related trials for Dry Eye
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingPhase 1/2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration, Geographic Atrophy
RecruitingObservational study
The Pathogenesis and Natural History of Sjogren's Disease
Sjogren's Syndrome, Salivary Gland
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jiayi Lee, MSc contact
Louis Tong, PhD principal investigator
Singapore Eye Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dry Eye and Meibomian Gland Dysfunction (Disorder), run by Singapore National Eye Centre at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Louis Tong Tong, PhD (65767200, louis.tong.h.t@singhealth.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy (time frame: Baseline visit and Post Baseline visit 3 months (+3 weeks).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026.